Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer

Overview of attention for article published in Frontiers in oncology, March 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 2 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 8,083 followers.

RT @radonclibrary: Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate…

31 Mar 2023

Reply Repost Favourite

RT @FrontOncology: New research: Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resis…

21 Mar 2023

Reply Repost Favourite

New research: Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer: Background Lutetium-177 [177Lu]-PSMA-617 is a targeted radioligand that binds to prostate-specific… https://t.co/

20 Mar 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.